Simplify Logo

Full-Time

Director – GXP Quality

Posted on 1/6/2024

Tango Therapeutics

Tango Therapeutics

51-200 employees

Develops targeted cancer therapies using CRISPR

Data & Analytics
Hardware
Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Communications
Quality Assurance (QA)
Requirements
  • Bachelor's Degree in a scientific discipline; advanced degree preferred
  • At least 8 years in the pharmaceutical industry with 5 years in GCP QA
  • Solid understanding of GCP, GLP, GVP, and ICH clinical requirements
  • Experience with US and international clinical studies
  • Able to travel domestically and internationally approximately 25% of the time
  • Excellent verbal and written communication skills including review of clinical documents
  • Good organizational skills and ability to work independently
  • Collaborative problem-solver
Responsibilities
  • Provide GCP/GLP/GVP QA oversight and support to cross functional teams
  • Schedule, oversee, and follow through routine and non-routine quality assurance audits including: investigator sites, CROs/ vendors, process, system, study project, and document reviews to assure quality assurance compliance with regard to all internal procedures as well as regulatory guidelines; will include conducting audits
  • Chair committee for the development, review, and approval of GCP/GLP/GVP controlled documents
  • Develop and implement detailed audit plans and yearly GCP/GLP/GVP audit schedules
  • Ensure timely and effective follow up of all identified or assigned quality issues
  • Act as a liaison with QA counterpart at CROs/vendors
  • Together with cross functional stakeholders assist in preparing for regulatory inspections
  • Conduct QA review of GCP protocols, ICFs, CSRs and other clinical trial specific documents
  • Conduct QA review of GLP reports and validation plans
  • Additional duties and responsibilities as required

Tango Therapeutics is developing novel cancer medicines using DNA sequencing and CRISPR-based target discovery to create breakthrough therapies that target specific tumor vulnerabilities, including loss of tumor suppressor gene function, multiple oncogenic drivers, and immune evasion, leveraging the principle of synthetic lethality. The company's approach focuses on expanding the reach of genetically targeted therapies to take direct aim at specific tumors.

Company Stage

IPO

Total Funding

$537M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

10%

1 year growth

23%

2 year growth

84%
INACTIVE